Growth PotentialThe company issued FY25 guidance at $42-$44M, demonstrating a growth rate in line with last year's, positioning SI in a strong position to capture market share.
Market PositioningSI reported results for the first time since the IPO, with net quarterly revenue of $11.0M, reflecting 33% YoY growth, attributed to the accelerating market adoption of its implant systems.
Product DifferentiationSI's product offerings are a compelling option for surgeons especially as shoulder arthroplasty shifts towards outpatient and ambulatory surgical care.
Technological AdvantageProVoyance, an industry-leading, AI-enabled pre-op planning tool, provides a competitive edge as enabling technology becomes more pertinent for the shoulder arthroplasty space.